Amneal Pharmaceuticals, Inc.
AMRX
$4.66
$0.358.12%
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 620.04M | 599.05M | 557.54M | 609.76M | 545.56M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 620.04M | 599.05M | 557.54M | 609.76M | 545.56M |
| Cost of Revenue | 388.40M | 379.85M | 370.00M | 390.41M | 352.04M |
| Gross Profit | 231.65M | 219.20M | 187.54M | 219.35M | 193.52M |
| SG&A Expenses | 113.01M | 105.57M | 102.10M | 102.16M | 100.07M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 73.00K | 13.00K | -1.22M | -1.47M | -1.32M |
| Total Operating Expenses | 542.85M | 523.23M | 509.56M | 533.01M | 501.02M |
| Operating Income | 77.19M | 75.82M | 47.98M | 76.75M | 44.53M |
| Income Before Tax | 22.96M | 29.66M | -9.43M | -7.66M | 2.18M |
| Income Tax Expenses | -2.08M | -23.00K | 668.00K | -1.80M | 4.57M |
| Earnings from Continuing Operations | 25.03M | 29.68M | -10.09M | -5.86M | -2.39M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -15.35M | -17.77M | 3.15M | 1.53M | -299.00K |
| Net Income | 9.68M | 11.92M | -6.94M | -4.33M | -2.69M |
| EBIT | 77.19M | 75.82M | 47.98M | 76.75M | 44.53M |
| EBITDA | 134.40M | 132.93M | 106.13M | 137.81M | 106.14M |
| EPS Basic | 0.06 | 0.08 | -0.05 | -0.03 | -0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | 0.04 | 0.15 | 0.01 |
| EPS Diluted | 0.06 | 0.08 | -0.05 | -0.03 | -0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | 0.04 | 0.15 | 0.01 |
| Average Basic Shares Outstanding | 154.22M | 153.74M | 152.11M | 151.48M | 151.39M |
| Average Diluted Shares Outstanding | 159.69M | 154.89M | 152.11M | 151.48M | 151.39M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
